Table 2.
Hormone | Type | All participants | VAR | TNP | |||
---|---|---|---|---|---|---|---|
OR (CI) | p | OR (CI) | p | OR (CI) | p | ||
Progesterone | Static | 1.11 (0.96–1.28) | .154 | 1.07 (0.89–1.30) | .479 | 1.15 (0.93–1.41) | .192 |
Progesterone | Change | 1.23 (1.05–1.45) | .010 | 1.13 (0.93–1.38) | .219 | 1.37 (1.05–1.78) | .020 |
Estradiol | Static | 1.05 (0.89–1.24) | .567 | 1.01 (0.83–1.24) | .891 | 1.09 (0.83–1.44) | .530 |
Estradiol | Change | 1.01 (0.84–1.20) | .947 | 0.93 (0.75–1.14) | .460 | 1.10 (0.83–1.46) | .508 |
P/E ratio | Static | 1.08 (0.93–1.26) | .301 | 1.07 (0.87–1.30) | .535 | 1.10 (0.87–1.39) | .426 |
P/E ratio | Change | 1.13 (1.02–1.26) | .021 | 1.06 (0.91–1.23) | .464 | 1.23 (1.05–1.45) | .009 |
TNP = transdermal nicotine patches; VAR = varenicline; OR = odds ratio; CI = confidence interval; P/E = progesterone/estradiol. Results shown are from design-adjusted models (adjusted for primary treatment assignment and visit number [time]).